logo-2GrowBlox Sciences, Inc is a development-stage company that offers cultivating and processing solutions to medical marijuana businesses. These solutions are primarily the proprietary technologies that the company itself has developed, and GrowBlox Sciences intends to implement these in Nevada through its state-level partners.

The company was founded in 2001 and first operated as Flagstick Ventures, Inc. It underwent various changes in business and name: in 2004, it became the Diabetic Treatment Centers of America, Inc, and in 2008, it changed to Signature Exploration and Production Corp. Finally, in April 2014, it became GrowBlox Sciences, Inc.

The company is now being traded in the OTC markets under the symbol GBLX. Its value is estimated at USD 22.41 M.

GrowBlox Sciences’ technologies cater to various aspects of the marijuana cultivation process. One of the company’s major technologies is the GrowBlox Cannabis Grow Chamber, an indoor plant-growing chamber equipped with climate and environment controls. The company also has the InCUBEator Cannabis Propagation Chamber, designed to ensure the consistency of cannabis cultivation through the tissue culture method.

Another solution developed by GrowBlox is the ConversionLAB, which is used in the extraction of the medicinal compounds of cannabis, utilizing CO2 to produce clean extracts. Finally, for the drying and curing of marijuana, there is the CureBLOX Cannabis Drying System. This process follows an algorithm that regulates temperature and humidity and thus makes the product pathogen-free.

In addition, GrowBlox is one of the leading companies that process state and local licenses in places where medical cannabis programs are established. The company does this with its specialists in application requests such as compliance, sales plans, packaging, branding, and security.

The management team at GrowBlox Sciences, Inc comprises CEO and Chairman Craig M. Ellins, CFO and Chief Accounting Officer Steven W. Weldon, and Chief Science Officer Dr. Andrea Small-Howard.


Yahoo! Finance: GBLX News

Latest Financial News for GBLX

GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/ ...

GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center ...

GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center

In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.

GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium

On November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products. LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the success of its first annual, "Innovation in Medical Cannabis Therapies" (IMCT) Symposium, held on Friday, November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.

GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars

LAS VEGAS, Dec. 12, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their first crop in the rapidly expanding hemp market expects to yield a gross profit of $0.7million dollars as well as seeds and genetics.  These seeds and genetic information will provide the mother plants in order to expand the program, which should prove to be a significant revenue generator for the Company. An integral part of the Company's success is its partnership with The Colorado Hemp Project (CHP). "GB Sciences told us what they wanted out of the plants, and we worked together to fill in the blanks," remarked Wild Bill.